CRISPR Therapeutics AG's (NASDAQ:CRSP) Recent 4.5% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures

Simply Wall StDec 31, 2024 21:31

CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?

Yahoo FinanceDec 29, 2024 19:36

Institutional Investors May Adopt Severe Steps After CRISPR Therapeutics AG's (NASDAQ:CRSP) Latest 8.3% Drop Adds to a Year Losses

Yahoo FinanceDec 25, 2024 20:07

SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?

Seeking AlphaDec 23, 2024 05:12

JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86

Futu NewsDec 21, 2024 02:31 · Ratings

CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing

TipRanksDec 21, 2024 01:58